
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

- Filed by the Registrant
Filed by a Party other than the Registrant
Check the appropriate box:
 Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material Pursuant to §240.14a-12

ACASTI PHARMA INC.

(Name of Registrant as Specified in its Charter)

Not Applicable

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
 Fee paid previously with preliminary materials.
 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
-
-
-



ACASTI PHARMA INC.
103 CARNEGIE CENTER
SUITE 300
PRINCETON, NEW JERSEY 08540

V53687-P14861

Your **Vote** Counts!

ACASTI PHARMA INC.

2024 Annual and Special Meeting
Vote online or by telephone by September 29, 2024
11:59 PM ET



You invested in ACASTI PHARMA INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual and Special Meeting. **This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held virtually on September 30, 2024.**

Get informed before you vote

We encourage you to access and review all of the important information contained in the proxy materials before voting. View the Notice and Proxy Statement and Annual Report online at www.ProxyVote.com and www.sedarplus.ca OR you can receive a free paper or email copy of the material(s) by requesting prior to September 16, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number



Vote Virtually at the Meeting*

September 30, 2024
10:00 AM ET

Virtually at:
www.virtualshareholdermeeting.com/ACST2024

*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. The complete proxy materials contain important information and are available at www.ProxyVote.com. Please follow the instructions on the reverse side to access and review the proxy materials and to vote on these important matters.

Voting Items	Board Recommends						
<p>1. Elect Vimal Kavuru, A. Brian Davis, S. George Kottayil, Prashant Kohli and Edward Neugeboren as directors of the Corporation to serve for a term that expires at the Corporation's 2025 annual meeting of shareholders or until his successor is elected or appointed.</p> <p>Nominees:</p> <table border="0"> <tr> <td>01) Vimal Kavuru</td> <td>04) Prashant Kohli</td> </tr> <tr> <td>02) A. Brian Davis</td> <td>05) Edward Neugeboren</td> </tr> <tr> <td>03) S. George Kottayil</td> <td></td> </tr> </table>	01) Vimal Kavuru	04) Prashant Kohli	02) A. Brian Davis	05) Edward Neugeboren	03) S. George Kottayil		<p>✔ For</p>
01) Vimal Kavuru	04) Prashant Kohli						
02) A. Brian Davis	05) Edward Neugeboren						
03) S. George Kottayil							
<p>2. Appoint KPMG LLP as the Corporation's independent registered public accounting firm until the close of the Corporation's 2025 annual meeting of shareholders and to authorize the board of directors of the Corporation to fix such independent registered public accounting firm's remuneration.</p>	<p>✔ For</p>						
<p>3. Adopt an advisory (non-binding) resolution on the compensation of the Corporation's named executive officers, as more particularly described in the Corporation's management information circular and proxy statement.</p>	<p>✔ For</p>						
<p>4. Approve, with or without variation, a special resolution (the "Continuance Resolution"), as set forth in the Corporation's management information circular and proxy statement, authorizing the continuance of the Corporation from the Province of Québec under the <i>Business Corporations Act</i> (Québec) to the Province of British Columbia under the <i>Business Corporations Act</i> (British Columbia) through the adoption of the continuation application containing the notice of articles and the articles, as set forth in the Corporation's management information circular and proxy statement, subject to and conditional upon the approval of the Domestication Resolution, all as more fully described in the Corporation's management information circular and proxy statement.</p>	<p>✔ For</p>						
<p>5. Approve, with or without variation, a special resolution (the "Domestication Resolution"), as set forth in the Corporation's management information circular and proxy statement, authorizing the domestication of the Corporation from the Province of British Columbia to the State of Delaware and the adoption of a certificate of corporate domestication and a new certificate of incorporation, as set forth in the Corporation's management information circular and proxy statement, subject to and conditional upon the approval of the Continuance Resolution, all as more fully described in the Corporation's management information circular and proxy statement.</p>	<p>✔ For</p>						
<p>6. Approve, subject to and conditional upon the approval of the Domestication Resolution, the Acasti Pharma Inc. 2024 Equity Incentive Plan, as set forth and more fully described in the Corporation's management information circular and proxy statement.</p>	<p>✔ For</p>						

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".